Watch out, Pomalyst: Amgen gets quick FDA review for lucrative new Kyprolis use
Amgen's hoping its blood cancer med Kyprolis can win an FDA bump-up from third-line treatment to second-line, and it won't have to wait long to find out whether its hopes pay off. The agency fast-tracked Amgen's application for the new use, which should give Amgen an answer by July 26, the company said. If Kyprolis passes muster, the second-line nod will open up a larger patient population that stays on treatment for a longer period of time. Read: bolstered sales
http://links.mkt1985.com/ctt?kn=106&ms=MTE3NTM5MzUS1&r=NTEzMTA5NTUzNjgS1&b=0&j=NDY0MzYyOTU3S0&mt=1&rt=0